In this section, we summarize preclinical evidence supporting TAAR1 agonists as a potential therapeutic candidate in schizophrenia that may offer differentiation from antipsychotics, which are limited to the efficacy and associated safety profile of D2 antagonism. The gene discussed is TAAR1; the disease is schizophrenia.